These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2495709)

  • 61. Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction.
    Sakamoto T; Yasue H; Ogawa H; Misumi I; Masuda T
    Am J Cardiol; 1992 Aug; 70(3):271-6. PubMed ID: 1632387
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion.
    Teirstein PS; Mann JT; Cundey PE; Schechter E; Jacobs WC; Grines CL; Stagaman DJ; Lansky AJ; Hultquist MA; Kusnick BA; Heuser RR; Kleinert HD; Popma J
    Am J Cardiol; 1999 Jun; 83(12):1623-8. PubMed ID: 10392865
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
    Nordt TK; Moser M; Kohler B; Ruef J; Peter K; Kübler W; Bode C
    Thromb Haemost; 1998 Dec; 80(6):881-6. PubMed ID: 9869154
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.
    Gurewich V; Pannell R; Simmons-Byrd A; Sarmientos P; Liu JN; Badylak SF
    J Thromb Haemost; 2006 Jul; 4(7):1559-65. PubMed ID: 16839354
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Coronary thrombolysis with urokinase infusion in acute myocardial infarction: multicenter study in Japan.
    Kambara H; Kawai C; Kammatsuse K; Sato H; Nobuyoshi M; Chino M; Miwa H; Uchida Y; Kodama K; Mitsudo K
    Cathet Cardiovasc Diagn; 1985; 11(4):349-60. PubMed ID: 3899371
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.
    Van de Werf F; Ludbrook PA; Bergmann SR; Tiefenbrunn AJ; Fox KA; de Geest H; Verstraete M; Collen D; Sobel BE
    N Engl J Med; 1984 Mar; 310(10):609-13. PubMed ID: 6537987
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.
    Collen D; Stump D; van de Werf F; Jang IK; Nobuhara M; Lijnen HR
    Circulation; 1985 Aug; 72(2):384-8. PubMed ID: 3924437
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A pilot study of urokinase therapy in cerebral infarction.
    Fletcher AP; Alkjaersig N; Lewis M; Tulevski V; Davies A; Brooks JE; Hardin WB; Landau WM; Raichle ME
    Stroke; 1976; 7(2):135-42. PubMed ID: 1265805
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Intravenous thrombolysis by urokinase in acute myocardial infarction].
    Onikura S; Kanmatsuse K; Kajiwara N
    Nihon Naika Gakkai Zasshi; 1985 Nov; 74(11):1512-21. PubMed ID: 3831178
    [No Abstract]   [Full Text] [Related]  

  • 70. Dose-ranging trial with a recombinant urokinase (urokinase alfa) for occluded central venous catheters in oncology patients.
    Deitcher SR; Fraschini G; Himmelfarb J; Schuman E; Smith TJ; Schulz GA; Firszt CM; Mouginis TL
    J Vasc Interv Radiol; 2004 Jun; 15(6):575-80. PubMed ID: 15178717
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Intravenous short-term coronary thrombolysis by a high-dose urokinase in aged patients with acute myocardial infarction].
    Sakai M; Matsushita S; Ueda K; Kuramoto K
    Nihon Ronen Igakkai Zasshi; 1987 Jul; 24(4):354-60. PubMed ID: 3682265
    [No Abstract]   [Full Text] [Related]  

  • 72. Life-threatening hemothorax in a child following intrapleural administration of urokinase.
    Blom D; van Aalderen WM; Alders JM; Hoekstra MO
    Pediatr Pulmonol; 2000 Dec; 30(6):493. PubMed ID: 11109063
    [No Abstract]   [Full Text] [Related]  

  • 73. A chromogenic enzymatic assay capable of detecting prourokinase-like material in plasma.
    Kebabian PR; Henkin J
    Thromb Res; 1992 Feb; 65(3):401-7. PubMed ID: 1631804
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Unanswered questions in thrombolysis.
    Chamberlain DA
    Am J Cardiol; 1989 Jul; 64(2):34A-40A; discussion 41A-42A. PubMed ID: 2662742
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of recombinant human prourokinase on thrombolysis in a rabbit model of thromboembolic stroke.
    Hao C; Ding W; Xu X; Sun Q; Li X; Wang W; Zhao Z; Tang L
    Biomed Rep; 2018 Jan; 8(1):77-84. PubMed ID: 29387392
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Febrile reaction associated with urokinase.
    Shibley MH; Clifton GD
    Pharmacotherapy; 1994; 14(1):123-5. PubMed ID: 8159597
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Enhancement of reciprocal activation of prourokinase and plasminogen by the bacterial lipopeptide surfactins and iturin Cs.
    Kikuchi T; Hasumi K
    J Antibiot (Tokyo); 2003 Jan; 56(1):34-7. PubMed ID: 12670048
    [No Abstract]   [Full Text] [Related]  

  • 78. Increased releasable vascular plasminogen activator and a bleeding diathesis.
    Walther PJ; Gore M; Pizzo SV
    Am J Med; 1984 Sep; 77(3):566-8. PubMed ID: 6540987
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment of intravenous thrombolysis with half-dose recombinant human prourokinase reduces the rate of tirofiban use during early routine catheterization period.
    Jiang C; Gao J; Luo DL; Guo JT
    Asian J Surg; 2022 Jul; 45(7):1414-1415. PubMed ID: 35440391
    [No Abstract]   [Full Text] [Related]  

  • 80. Polylactide-Based Stent Coatings: Biodegradable Polymeric Coatings Capable of Maintaining Sustained Release of the Thrombolytic Enzyme Prourokinase.
    Baikin AS; Kolmakov AG; Shatova LA; Nasakina EO; Sharapov MG; Baymler IV; Gudkov SV; Sevostyanov MA
    Materials (Basel); 2019 Dec; 12(24):. PubMed ID: 31818007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.